PURPOSE: To identify the incidence and the risk factors for pulmonary toxicity in children treated for cancer with contemporary lung irradiation. METHODS AND MATERIALS: We analyzed clinical features, radiographic findings, pulmonary function tests, and dosimetric parameters of children receiving irradiation to the lung fields over a 10-year period. RESULTS: We identified 109 patients (75 male patients). The median age at irradiation was 13.8 years (range, 0.04-20.9 years). The median follow-up period was 3.4 years. The median prescribed radiation dose was 21 Gy (range, 0.4-64.8 Gy). Pulmonary toxic chemotherapy included bleomycin in 58.7% of patients and cyclophosphamide in 83.5%. The following pulmonary outcomes were identified and the 5-year cumulative incidence after irradiation was determined: pneumonitis, 6%; chronic cough, 10%; pneumonia, 35%; dyspnea, 11%; supplemental oxygen requirement, 2%; radiographic interstitial lung disease, 40%; and chest wall deformity, 12%. One patient died of progressive respiratory failure. Post-irradiation pulmonary function tests available from 44 patients showed evidence of obstructive lung disease (25%), restrictive disease (11%), hyperinflation (32%), and abnormal diffusion capacity (12%). Thoracic surgery, bleomycin, age, mean lung irradiation dose (MLD), maximum lung dose, prescribed dose, and dosimetric parameters between V22 (volume of lung exposed to a radiation dose ≥22 Gy) and V30 (volume of lung exposed to a radiation dose ≥30 Gy) were significant for the development of adverse pulmonary outcomes on univariate analysis. MLD, maximum lung dose, and Vdose (percentage of volume of lung receiving the threshold dose or greater) were highly correlated. On multivariate analysis, MLD was the sole significant predictor of adverse pulmonary outcome (P=.01). CONCLUSIONS: Significant pulmonary dysfunction occurs in children receiving lung irradiation by contemporary techniques. MLD rather than prescribed dose should be used to perform risk stratification of patients receiving lung irradiation.
PURPOSE: To identify the incidence and the risk factors for pulmonary toxicity in children treated for cancer with contemporary lung irradiation. METHODS AND MATERIALS: We analyzed clinical features, radiographic findings, pulmonary function tests, and dosimetric parameters of children receiving irradiation to the lung fields over a 10-year period. RESULTS: We identified 109 patients (75 male patients). The median age at irradiation was 13.8 years (range, 0.04-20.9 years). The median follow-up period was 3.4 years. The median prescribed radiation dose was 21 Gy (range, 0.4-64.8 Gy). Pulmonary toxic chemotherapy included bleomycin in 58.7% of patients and cyclophosphamide in 83.5%. The following pulmonary outcomes were identified and the 5-year cumulative incidence after irradiation was determined: pneumonitis, 6%; chronic cough, 10%; pneumonia, 35%; dyspnea, 11%; supplemental oxygen requirement, 2%; radiographic interstitial lung disease, 40%; and chest wall deformity, 12%. One patient died of progressive respiratory failure. Post-irradiation pulmonary function tests available from 44 patients showed evidence of obstructive lung disease (25%), restrictive disease (11%), hyperinflation (32%), and abnormal diffusion capacity (12%). Thoracic surgery, bleomycin, age, mean lung irradiation dose (MLD), maximum lung dose, prescribed dose, and dosimetric parameters between V22 (volume of lung exposed to a radiation dose ≥22 Gy) and V30 (volume of lung exposed to a radiation dose ≥30 Gy) were significant for the development of adverse pulmonary outcomes on univariate analysis. MLD, maximum lung dose, and Vdose (percentage of volume of lung receiving the threshold dose or greater) were highly correlated. On multivariate analysis, MLD was the sole significant predictor of adverse pulmonary outcome (P=.01). CONCLUSIONS: Significant pulmonary dysfunction occurs in children receiving lung irradiation by contemporary techniques. MLD rather than prescribed dose should be used to perform risk stratification of patients receiving lung irradiation.
Authors: Daniel M Green; Thomas E Merchant; Catherine A Billups; Dennis C Stokes; Alberto Broniscer; Ute Bartels; Murali Chintagumpala; Timothy E Hassall; Sridharan Gururangan; Geoffrey B McCowage; John A Heath; Richard J Cohn; Michael J Fisher; Ashok Srinivasan; Giles W Robinson; Amar Gajjar Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-19 Impact factor: 7.038
Authors: HaiThuy N Nguyen; Shailendra Das; Maria C Gazzaneo; Ernestina Melicoff; George B Mallory; Karen W Eldin; R Paul Guillerman Journal: Pediatr Radiol Date: 2019-04-19
Authors: Sander Roberti; Flora E van Leeuwen; Cécile M Ronckers; Inge M Krul; Florent de Vathaire; Cristina Veres; Ibrahima Diallo; Cécile P M Janus; Berthe M P Aleman; Nicola S Russell; Michael Hauptmann Journal: J Natl Cancer Inst Date: 2022-09-09 Impact factor: 11.816
Authors: Rahel Kasteler; Christa Lichtensteiger; Christina Schindera; Marc Ansari; Claudia E Kuehni Journal: BMC Cancer Date: 2021-07-08 Impact factor: 4.430